Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ew-7197
2. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline
1. 1352608-82-2
2. Ew-7197
3. Ew 7197
4. Tew-7197
5. Tew 7197
6. Ew7197
7. Chembl3260567
8. 6t4o391p5y
9. 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline
10. N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline
11. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine
12. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine
13. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline
14. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]methyl]-2-fluoroaniline
15. Vactosertib [inn]
16. Vactosertib [who-dd]
17. Schembl250076
18. Unii-6t4o391p5y
19. Gtpl8107
20. Dtxsid401010181
21. Hms3674i03
22. Bcp18384
23. Ex-a1738
24. Nov-1301
25. Am9667
26. Bdbm50015639
27. Mfcd28348363
28. S7530
29. Akos027250746
30. Zinc113391423
31. Ccg-264709
32. Cs-5679
33. Db15310
34. Sb17272
35. Ncgc00386413-01
36. Ncgc00386413-02
37. Ac-29028
38. As-10150
39. Bt168124
40. Hy-19928
41. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methyl-2-pyridyl)-2-imidazolyl]methyl]-2-fluoroaniline
42. Sy235585
43. Ds-001727
44. A14213
45. Q27077252
46. 1h-imidazole-2-methanamine, N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-(1,2,4)triazolo(1,5-a)pyridin-6-yl-
47. 1h-imidazole-2-methanamine,n-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-
48. 2-fluoro-n-((4-(6-methylpyridin-2-yl)-5-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-1h-imidazol-2-yl)methyl)aniline
49. N-((5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline
50. N-(2-fluorophenyl)-4-([1,2,4]triazolo[1,5-a]pyridine-6-yl)-5-(6-methyl-2-pyridyl)-1h-imidazole-2-methaneamine
| Molecular Weight | 399.4 g/mol |
|---|---|
| Molecular Formula | C22H18FN7 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 399.16077177 g/mol |
| Monoisotopic Mass | 399.16077177 g/mol |
| Topological Polar Surface Area | 83.8 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 566 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Vactosertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vactosertib, including repackagers and relabelers. The FDA regulates Vactosertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vactosertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vactosertib supplier is an individual or a company that provides Vactosertib active pharmaceutical ingredient (API) or Vactosertib finished formulations upon request. The Vactosertib suppliers may include Vactosertib API manufacturers, exporters, distributors and traders.
Vactosertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vactosertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vactosertib GMP manufacturer or Vactosertib GMP API supplier for your needs.
A Vactosertib CoA (Certificate of Analysis) is a formal document that attests to Vactosertib's compliance with Vactosertib specifications and serves as a tool for batch-level quality control.
Vactosertib CoA mostly includes findings from lab analyses of a specific batch. For each Vactosertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vactosertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vactosertib EP), Vactosertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vactosertib USP).
LOOKING FOR A SUPPLIER?
